78 results
6-K
EX-99.1
REPCF
Replicel Life Sciences Inc.
30 Nov 23
Condensed Consolidated Interim Financial Statements
1:05pm
focused on developing autologous cell therapies that treat functional cellular deficits including chronic tendon injuries, androgenetic alopecia and skin
6-K
EX-99.2
REPCF
Replicel Life Sciences Inc.
30 Nov 23
Condensed Consolidated Interim Financial Statements
1:05pm
may, among other things, include the Company's:
belief that chronic tendon injuries resulting from sports-related or occupational overuse … fails to provide a satisfactory solution to this chronic condition.
Treatment
The Company believes chronic tendon injuries resulting from sports-related
6-K
EX-99.1
REPCF
Replicel Life Sciences Inc.
24 Oct 23
Condensed Consolidated Interim Financial Statements
11:10am
cellular deficits including chronic tendon injuries, androgenetic alopecia and skin aging.
The Company's corporate office and principal place
6-K
EX-99.2
REPCF
Replicel Life Sciences Inc.
24 Oct 23
Condensed Consolidated Interim Financial Statements
11:10am
things, include the Company's:
belief that chronic tendon injuries resulting from sports-related or occupational overuse is a significant unmet medical … to provide a satisfactory solution to this chronic condition.
Treatment
The Company believes that chronic tendon injuries resulting from sports-related
6-K
EX-99.2
REPCF
Replicel Life Sciences Inc.
30 May 23
Condensed Consolidated Interim Financial Statements
5:40pm
presented in such statements or disclosures may, among other things, include the Company's:
belief that chronic tendon injuries resulting from sports … -
Treatment
The Company believes that chronic tendon injuries resulting from sports-related or occupational overuse is a significant unmet medical need
6-K
EX-99.1
lvuk9v
30 May 23
Condensed Consolidated Interim Financial Statements
5:40pm
6-K
EX-99.2
5hw3 8260
29 Nov 22
Condensed Consolidated Interim Financial Statements
6:44pm
6-K
EX-99.1
9qqnc8tv2pyv5 rqvm6
29 Nov 22
Condensed Consolidated Interim Financial Statements
6:44pm
20-F/A
f8zt1chv5cwud
12 Sep 22
Annual report (foreign) (amended)
6:17pm
6-K
EX-99.2
ae42zjk2gc kp665no
6 Sep 22
Condensed Consolidated Interim Financial Statements
12:42pm
6-K
EX-99.1
b71k8x bwqtwb0tw
6 Sep 22
Condensed Consolidated Interim Financial Statements
12:42pm
6-K
EX-99.4
1ndpht6aa9t33ji
7 Jul 22
RepliCel Provides Update on Private Placement
3:36pm
6-K
EX-99.3
a0306hh3
7 Jul 22
RepliCel Provides Update on Private Placement
3:36pm
6-K
EX-99.2
0wx5o06jvewzw8sqo41g
30 Nov 21
Condensed Consolidated Interim Financial Statements
1:50pm
6-K
EX-99.1
gnwfj6 kcgisp
30 Nov 21
Condensed Consolidated Interim Financial Statements
1:50pm
6-K
EX-99.2
zaq4186ga4yff
31 Aug 21
Condensed Consolidated Interim Financial Statements
1:45pm
6-K
EX-99.1
y1vpb7kvcphoku
31 Aug 21
Condensed Consolidated Interim Financial Statements
1:45pm
6-K
EX-99.1
25zf7zgai
1 Jun 21
Condensed Consolidated Interim Financial Statements
3:57pm